ClinicalTrials.Veeva

Menu

Effect of Lidocaine Block on Gastroesophageal Reflux Disease

M

Muhammad

Status

Not yet enrolling

Conditions

Gastroesophageal Reflux Disease

Treatments

Procedure: Injection
Drug: Lidocaine hydrochloride
Behavioral: Rehabilitation therapy

Study type

Interventional

Funder types

Other

Identifiers

NCT06304142
SGB-reflux

Details and patient eligibility

About

The goal of this clinical trial is to explore Clinical Effect of Stellate Ganglion Block on Gastroesophageal Reflux Disease. The main question it aims to answer is:

• Can stellate ganglion block improve gastroesophageal reflux symptoms better on the basis of rehabilitation training? Participants will be randomly allocated into the control group or the experimental group, all under rehabilitation treatment, the experimental group will be given Stellate Ganglion Block once a day additionally. The study lasts 10 days for each participant. Researchers will compare the Gastroesophageal Reflux Disease Questionnaire, Pressure pain threshold, Self-Evaluation Questionnaire for Gastroesophageal Reflux Disease, to see if the Stellate Ganglion Block can help improve the symptom.

Full description

Gastroesophageal reflux is a common digestive disorder characterized by the backflow of stomach contents and fluids into the esophagus.

The goal of this clinical trial is to explore Clinical Effect of Stellate Ganglion Block on Gastroesophageal Reflux Disease. The main question it aims to answer is:

• Can stellate ganglion block improve gastroesophageal reflux symptoms better on the basis of rehabilitation training? Participants will be randomly allocated into the control group or the experimental group, all under rehabilitation treatment, the experimental group will be given Stellate Ganglion Block once a day additionally. The study lasts 10 days for each participant. Researchers will compare the Gastroesophageal Reflux Disease Questionnaire, Pressure pain threshold, Self-Evaluation Questionnaire for Gastroesophageal Reflux Disease, to see if the Stellate Ganglion Block can help improve the symptom.

Enrollment

80 estimated patients

Sex

All

Ages

18 to 80 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Gastroesophageal Reflux Disease diagnosis
  • aged between 18 and 80 years old.
  • subjects who tolerate cervical movements in sitting position.
  • stable vital signs.
  • normal consciousness

Exclusion criteria

  • contraindications for stellate ganglion block.
  • peptic ulcer.
  • previous or present gastric cancer.
  • previous gastric surgery.
  • recent fractures or cervical trauma.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Quadruple Blind

80 participants in 2 patient groups, including a placebo group

Rehabilitation therapy+Stellate ganglion block
Experimental group
Description:
The study lasts 10 days for each patient. During the treatment, All the participants are provided with the rehabilitation therapy. Based on this, the patients in the experimental group are provided with Stellate Ganglion Block , using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g), once a day.
Treatment:
Procedure: Injection
Behavioral: Rehabilitation therapy
Drug: Lidocaine hydrochloride
Rehabilitation therapy+placebo block
Placebo Comparator group
Description:
The study lasts 20d for each patient. During the treatment, All the participants are provided with the rehabilitation therapy. This group will be additionally provided with placebo block without any drugs.
Treatment:
Procedure: Injection
Behavioral: Rehabilitation therapy

Trial contacts and locations

1

Loading...

Central trial contact

Lavie Ce, Master

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems